Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT03602612
First seen Mar 03, 2026 · Last updated Apr 30, 2026 · Updated 8 times
Summary
This early-phase study tests the safety of a new gene therapy for adults with multiple myeloma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack myeloma cells. Participants receive chemotherapy before the modified cells are infused, and they are monitored closely for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.